Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - CA
$ 1.99
1.02 %
$ 761 M
Market Cap
-16.58
P/E
1. INTRINSIC VALUE
Balance Sheet
Cronos Group Inc.
| Current Assets | 933 M |
| Cash & Short-Term Investments | 862 M |
| Receivables | 35.9 M |
| Other Current Assets | 35.9 M |
| Non-Current Assets | 207 M |
| Long-Term Investments | 54.7 M |
| PP&E | 60.5 M |
| Other Non-Current Assets | 91.5 M |
| Current Liabilities | 41.4 M |
| Accounts Payable | 12.1 M |
| Short-Term Debt | 994 K |
| Other Current Liabilities | 28.3 M |
| Non-Current Liabilities | 2.56 M |
| Long-Term Debt | 1.56 M |
| Other Non-Current Liabilities | 1 M |
EFFICIENCY
Earnings Waterfall
Cronos Group Inc.
| Revenue | 87.2 M |
| Cost Of Revenue | 75.3 M |
| Gross Profit | 11.9 M |
| Operating Expenses | 96.7 M |
| Operating Income | -84.8 M |
| Other Expenses | -10.2 M |
| Net Income | -74.6 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Cronos Group Inc.
| Net Income | -74.6 M |
| Depreciation & Amortization | 8.11 M |
| Capital Expenditures | -3.42 M |
| Stock-Based Compensation | 8.77 M |
| Change in Working Capital | -26.5 M |
| Others | -979 K |
| Free Cash Flow | -46.3 M |
Wall Street Analysts Price Targets
Cronos Group Inc.
Wall Street analysts predict an average 1-year price target for CRON of $3.15 , with forecasts ranging from
a
low of
$2.3 to a high of $4.5 .
CRON Lowest Price Target
Wall Street Target
2.3 USD
15.58%
CRON Average Price Target
Wall Street Target
3.15 USD
58.29%
CRON Highest Price Target
Wall Street Target
4.5 USD
126.13%
4. DIVIDEND
ANALYSIS
CRON does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Cronos Group Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
1 year ago
May 30, 2023
|
Bought
45.6 K USD
|
ADLER JASON MARC
Director
|
+ 26250
|
1.7353 USD |
|
1 year ago
May 30, 2023
|
Bought
19.5 K USD
|
ADLER JASON MARC
Director
|
+ 11250
|
1.7353 USD |
|
1 year ago
May 25, 2023
|
Bought
126 K USD
|
ADLER JASON MARC
Director
|
+ 69999
|
1.7965 USD |
|
1 year ago
May 25, 2023
|
Bought
53.9 K USD
|
ADLER JASON MARC
Director
|
+ 30001
|
1.7965 USD |
|
1 year ago
May 23, 2023
|
Bought
133 K USD
|
ADLER JASON MARC
Director
|
+ 69999
|
1.9022 USD |
|
1 year ago
May 23, 2023
|
Bought
57.1 K USD
|
ADLER JASON MARC
Director
|
+ 30001
|
1.9022 USD |
|
1 year ago
May 19, 2023
|
Bought
132 K USD
|
ADLER JASON MARC
Director
|
+ 70000
|
1.8901 USD |
|
1 year ago
May 19, 2023
|
Bought
56.7 K USD
|
ADLER JASON MARC
Director
|
+ 30000
|
1.8901 USD |
|
1 year ago
May 18, 2023
|
Bought
14.4 K USD
|
ADLER JASON MARC
Director
|
+ 7994
|
1.7982 USD |
|
1 year ago
May 17, 2023
|
Bought
71 K USD
|
ADLER JASON MARC
Director
|
+ 41505
|
1.7118 USD |
|
1 year ago
May 18, 2023
|
Bought
6.16 K USD
|
ADLER JASON MARC
Director
|
+ 3426
|
1.7982 USD |
|
1 year ago
May 17, 2023
|
Bought
30.5 K USD
|
ADLER JASON MARC
Director
|
+ 17795
|
1.7118 USD |
|
1 year ago
May 16, 2023
|
Bought
91.5 K USD
|
ADLER JASON MARC
Director
|
+ 53269
|
1.7176 USD |
|
1 year ago
May 15, 2023
|
Bought
23.3 K USD
|
ADLER JASON MARC
Director
|
+ 13300
|
1.7556 USD |
|
1 year ago
May 16, 2023
|
Bought
39.2 K USD
|
ADLER JASON MARC
Director
|
+ 22831
|
1.7176 USD |
|
1 year ago
May 15, 2023
|
Bought
10 K USD
|
ADLER JASON MARC
Director
|
+ 5700
|
1.7556 USD |
|
2 years ago
Dec 15, 2022
|
Bought
215 K USD
|
ADLER JASON MARC
Director
|
+ 76711
|
2.8067 USD |
|
2 years ago
Dec 14, 2022
|
Bought
187 K USD
|
ADLER JASON MARC
Director
|
+ 66219
|
2.8288 USD |
|
2 years ago
Dec 15, 2022
|
Bought
92.3 K USD
|
ADLER JASON MARC
Director
|
+ 32877
|
2.8067 USD |
|
2 years ago
Dec 14, 2022
|
Bought
80.3 K USD
|
ADLER JASON MARC
Director
|
+ 28381
|
2.8288 USD |
|
2 years ago
Dec 13, 2022
|
Bought
178 K USD
|
ADLER JASON MARC
Director
|
+ 61706
|
2.8925 USD |
|
2 years ago
Dec 12, 2022
|
Bought
174 K USD
|
ADLER JASON MARC
Director
|
+ 60199
|
2.8951 USD |
|
2 years ago
Dec 13, 2022
|
Bought
76.5 K USD
|
ADLER JASON MARC
Director
|
+ 26446
|
2.8925 USD |
|
2 years ago
Dec 12, 2022
|
Bought
74.7 K USD
|
ADLER JASON MARC
Director
|
+ 25801
|
2.8951 USD |
|
2 years ago
Dec 09, 2022
|
Bought
261 K USD
|
ADLER JASON MARC
Director
|
+ 90299
|
2.8917 USD |
|
2 years ago
Dec 08, 2022
|
Bought
325 K USD
|
ADLER JASON MARC
Director
|
+ 113679
|
2.8608 USD |
|
2 years ago
Dec 09, 2022
|
Bought
112 K USD
|
ADLER JASON MARC
Director
|
+ 38701
|
2.8917 USD |
|
2 years ago
Dec 08, 2022
|
Bought
139 K USD
|
ADLER JASON MARC
Director
|
+ 48721
|
2.8608 USD |
|
2 years ago
Dec 07, 2022
|
Bought
244 K USD
|
ADLER JASON MARC
Director
|
+ 83299
|
2.9327 USD |
|
2 years ago
Dec 06, 2022
|
Bought
78.6 K USD
|
ADLER JASON MARC
Director
|
+ 25900
|
3.0345 USD |
|
2 years ago
Dec 07, 2022
|
Bought
105 K USD
|
ADLER JASON MARC
Director
|
+ 35701
|
2.9327 USD |
|
2 years ago
Dec 06, 2022
|
Bought
33.7 K USD
|
ADLER JASON MARC
Director
|
+ 11100
|
3.0345 USD |
|
2 years ago
Nov 30, 2022
|
Bought
14.5 K USD
|
ADLER JASON MARC
Director
|
+ 4760
|
3.0465 USD |
|
2 years ago
Nov 30, 2022
|
Bought
6.21 K USD
|
ADLER JASON MARC
Director
|
+ 2040
|
3.0465 USD |
|
2 years ago
Nov 29, 2022
|
Bought
64.3 K USD
|
ADLER JASON MARC
Director
|
+ 21140
|
3.0413 USD |
|
2 years ago
Nov 28, 2022
|
Bought
48.1 K USD
|
ADLER JASON MARC
Director
|
+ 15890
|
3.0268 USD |
|
2 years ago
Nov 29, 2022
|
Bought
27.6 K USD
|
ADLER JASON MARC
Director
|
+ 9060
|
3.0413 USD |
|
2 years ago
Nov 28, 2022
|
Bought
20.6 K USD
|
ADLER JASON MARC
Director
|
+ 6810
|
3.0268 USD |
|
2 years ago
Nov 23, 2022
|
Bought
7.46 K USD
|
ADLER JASON MARC
Director
|
+ 2450
|
3.0429 USD |
|
2 years ago
Nov 22, 2022
|
Bought
106 K USD
|
ADLER JASON MARC
Director
|
+ 34860
|
3.0357 USD |
|
2 years ago
Nov 23, 2022
|
Bought
3.2 K USD
|
ADLER JASON MARC
Director
|
+ 1050
|
3.0429 USD |
|
2 years ago
Nov 22, 2022
|
Bought
45.4 K USD
|
ADLER JASON MARC
Director
|
+ 14940
|
3.0357 USD |
|
2 years ago
Nov 18, 2022
|
Bought
62.7 K USD
|
ADLER JASON MARC
Director
|
+ 20580
|
3.0445 USD |
|
2 years ago
Nov 17, 2022
|
Bought
166 K USD
|
ADLER JASON MARC
Director
|
+ 56699
|
2.935 USD |
|
2 years ago
Nov 18, 2022
|
Bought
26.9 K USD
|
ADLER JASON MARC
Director
|
+ 8820
|
3.0445 USD |
|
2 years ago
Nov 17, 2022
|
Bought
71.3 K USD
|
ADLER JASON MARC
Director
|
+ 24301
|
2.935 USD |
|
2 years ago
Nov 16, 2022
|
Bought
230 K USD
|
ADLER JASON MARC
Director
|
+ 77601
|
2.9656 USD |
|
2 years ago
Nov 15, 2022
|
Bought
368 K USD
|
ADLER JASON MARC
Director
|
+ 118998
|
3.0963 USD |
|
2 years ago
Nov 16, 2022
|
Bought
98.6 K USD
|
ADLER JASON MARC
Director
|
+ 33259
|
2.9656 USD |
|
2 years ago
Nov 15, 2022
|
Bought
158 K USD
|
ADLER JASON MARC
Director
|
+ 51002
|
3.0963 USD |
|
3 years ago
Mar 17, 2021
|
Sell 7.19 M
USD
|
ADLER JASON MARC
Director
|
- 714759
|
10.0657 USD |
|
3 years ago
Mar 15, 2021
|
Sell 4.82 M
USD
|
ADLER JASON MARC
Director
|
- 452810
|
10.6527 USD |
|
3 years ago
Mar 11, 2021
|
Sell 3.31 M
USD
|
GORENSTEIN MICHAEL RYAN
Executive Chairman
|
- 324411
|
10.1954 USD |
|
3 years ago
Mar 12, 2021
|
Sell 1.55 M
USD
|
GORENSTEIN MICHAEL RYAN
Executive Chairman
|
- 150000
|
10.3498 USD |
|
3 years ago
Mar 15, 2021
|
Sell 1.4 M
USD
|
GORENSTEIN MICHAEL RYAN
Executive Chairman
|
- 130000
|
10.7315 USD |
|
3 years ago
Mar 09, 2021
|
Sell 1.85 M
USD
|
GORENSTEIN MICHAEL RYAN
Executive Chairman
|
- 185000
|
9.9962 USD |
|
3 years ago
Mar 02, 2021
|
Sell 2.54 M
USD
|
GORENSTEIN MICHAEL RYAN
Executive Chairman
|
- 230000
|
11.0458 USD |
|
3 years ago
Mar 03, 2021
|
Sell 1.18 M
USD
|
GORENSTEIN MICHAEL RYAN
Executive Chairman
|
- 114015
|
10.3869 USD |
|
3 years ago
Mar 01, 2021
|
Sell 61.2 K
USD
|
JACOBSON JEFFREY DAVID
See Remarks
|
- 4500
|
13.6002 USD |
|
4 years ago
Nov 17, 2020
|
Sell 733 K
USD
|
ADLER JASON MARC
Director
|
- 100000
|
7.334 USD |
|
4 years ago
Nov 11, 2020
|
Sell 67.9 K
USD
|
ADLER JASON MARC
Director
|
- 9300
|
7.3 USD |
|
4 years ago
Nov 06, 2020
|
Sell 760 K
USD
|
ADLER JASON MARC
Director
|
- 100000
|
7.6018 USD |
|
4 years ago
Nov 09, 2020
|
Sell 5.95 M
USD
|
ADLER JASON MARC
Director
|
- 769339
|
7.7291 USD |
|
4 years ago
Nov 10, 2020
|
Sell 156 K
USD
|
ADLER JASON MARC
Director
|
- 21361
|
7.3005 USD |
|
4 years ago
Nov 06, 2020
|
Sell 8.46 M
USD
|
GORENSTEIN MICHAEL RYAN
Executive Chairman
|
- 1181499
|
7.1621 USD |
|
4 years ago
Nov 06, 2020
|
Sell 854 K
USD
|
GORENSTEIN MICHAEL RYAN
Executive Chairman
|
- 107851
|
7.9177 USD |
|
4 years ago
Aug 07, 2020
|
Bought
86.8 K USD
|
ABRAHAM TODD KEVIN
Chief Innovation Officer
|
+ 15000
|
5.7837 USD |
7. News
Top Canadian Marijuana Stocks For Your 2025 Watchlist
Most marijuana stock investors are excited about the upcoming trading year. 2025 has lots of potential in various fashions that are keeping hopes high for investors and legal operators. To start there has been an increase in demand for more cannabis products. As well as more companies turning higher profits and breaking records almost every quarter. What this does is show others that the cannabis sector regardless of its downtrend is a space where ultimately money can be made. Yet with the large amount of volatile trading, it's been tough to take profits.
marijuanastocks.com
- 3 weeks ago
2025 Outlook: The Best Canadian Cannabis Stocks to Watch Now
The cannabis industry continues to evolve rapidly, presenting unique investment opportunities, especially in Canadian cannabis stocks. With the U.S. cannabis market projected to exceed $40 billion by 2025, legalization efforts are gaining traction. Recent news highlights growing bipartisan support for federal cannabis reform in the U.S., which could further boost industry expansion. Canadian cannabis companies, with their well-established infrastructure and international presence, are strategically positioned to capitalize on this growth. Tracking key stocks with solid fundamentals and technical setups becomes essential as investors look for potential gains.
marijuanastocks.com
- 3 weeks ago
3 Marijuana Stocks For Your Holiday Trading
What are marijuana stock investors searching for this holiday season? For starters, some companies have recently reported strong quarterly earnings. The better a company performs, the more intriguing it looks to people to invest in it. Right now, many cannabis companies are making headway outside of the public sector. For instance, there has been a rapid expansion of dispensaries opening across the United States.
marijuanastocks.com
- 1 month ago
Why Cronos Group Stock Popped 9% Today
Cronos stock just went up -- a lot. Maybe it's time to sell?
fool.com
- 2 months ago
Cronos Group Inc. (CRON) Q3 2024 Earnings Call Transcript
Cronos Group Inc. (NASDAQ:CRON ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Anna Shlimak - Chief Strategy Officer Mike Gorenstein - Chairman, President and CEO James Holm - CFO Conference Call Participants Matt Bottomley - Canaccord Genuity Bill Kirk - Roth Capital Partners Operator Good morning. My name is Brianna and I will be your conference operator today.
seekingalpha.com
- 2 months ago
Cannabis stocks plunge after DeSantis, Griffin win Florida fight against weed legalization
Amendment 3 – which would have legalized the recreational use of marijuana in the state's constitution – failed to receive the 60% support needed to pass under Florida law.
nypost.com
- 2 months ago
Cannabis stocks tank as Florida votes against recreational marijuana
Shares in cannabis stocks such as Trulieve Cannabis Corp. (CSE:TRUL), Curaleaf Hldgs Inc. (CSE:CURA, OTCQX:CURLF) and Verano Holdings Corp (CSE:VRNO, OTCQX:VRNOF) tanked after Florida rejected legalization of recreational marijuana. A ballot measure, known as Amendment 3, which would have allowed adults to possess up to three ounces of marijuana, failed to obtain the required 60% of support from voters yesterday.
proactiveinvestors.com
- 2 months ago
Top Canadian Cannabis Stocks to Track as U.S. Legalization Heats Up
As the election approaches, Canadian cannabis stocks are capturing attention, especially with potential U.S. legalization developments on the horizon. The U.S. cannabis industry is booming, with projected growth reaching $41 billion by 2025. This massive market is appealing to Canadian companies seeking new revenue streams. Florida, in particular, is considering the legalization of recreational cannabis, which could unlock significant growth for Canadian cannabis companies with existing U.S. ties. If Florida joins the ranks of legal states, Canadian companies like Tilray, Canopy Growth, and Cronos Group could capitalize on this opportunity. These stocks are increasingly appealing to investors looking to benefit from potential changes in the U.S. market.
marijuanastocks.com
- 2 months ago
5 Stocks Backed by High Efficiency for Solid Gains Amid Volatility
Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels.
zacks.com
- 2 months ago
Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024
TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.
globenewswire.com
- 2 months ago
Spinach® Is the Number One Cannabis Brand in Canada
TORONTO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabinoid company, is proud to announce that its award-winning brand Spinach® has risen to the best-selling cannabis brand in the Canadian market.1 Spinach's market share outperformance represents Cronos' relentless commitment to quality, innovation, and bringing differentiated products to the competitive Canadian adult-use market.
globenewswire.com
- 3 months ago
3 Cannabis Stocks to Monitor as the Election Approaches
For most of the campaign cycle, those bullish on cannabis stocks viewed a Vice President Kamala Harris presidency as the most beneficial to the sector.
schaeffersresearch.com
- 3 months ago
8. Profile
Summary
Cronos Group Inc. CRON
COUNTRY
CA
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 761 M
Dividend Yield
0.00%
Description
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Contact
111 Peter Street, Toronto, ON, M5V 2H1
https://www.thecronosgroup.com
IPO
Date
Feb. 27, 2018
Employees
356
Officers
Mr. James Andrew McGinness III
Vice President, Controller & Principal Accounting Officer
Ms. Shannon Buggy
Senior Vice President & Global Head of People
Mr. James Holm
Chief Financial Officer
Mr. Jeffrey David Jacobson
Chief Growth Officer
Ms. Anna Shlimak
Chief Strategy Officer
Mr. Adam Wagner
Senior Vice President & Head of Cronos Israel
Mr. Terry Gregory-Joseph Doucet
General Counsel & Corporate Secretary
Mr. Arye Weigensberg
Senior Vice President and Head of Research & Development
Mr. Michael Ryan Gorenstein J.D.
President, Chief Executive Officer & Chairman
Mr. Shayne J. Laidlaw
Director of Investor Relations & Strategy